Member Info for Gizzard

The MMs aren't sure what to do with this, every dip is bought into so the bid is all over the place, but fundamentally it's such a sound business now the numbers speak for themselves. You got to laff - frying tonight.

Hi bb there are a load of t i t s around at the mo, no common sense just purile garbage.

And with a name like that he'll be burnt.

Absolute bargain down here, directors in at a higher price, debt paid off, more revenue due - fantastic opportunity.
No ramp just cheap...

You not right in the head 120M sales 161M market cap more sales due from the USA

Masses of monet generating news!

Novacyt is also pleased with the progress it is making in the US market and expects to update the market in due course.

During the last few weeks, Novacyt has secured registrations and regulatory approvals in the following new markets for its COVID-19 test: Panama, Ecuador, Columbia, Peru, Paraguay and the UAE.

The mobile COVID-19 testing solution is a combination of Exsig™ Direct and the COVID-19 test optimised to run on the Company's proprietary q16 and q32 instrumentation. Both Exsig™ extraction reagents are on track to launch during June 2020 and the mobile COVID-19 system will launch in July 2020.

So it's got sales to date of 120M with a mcap of 161M absolute no brainer at this level added thank you. And more sales to come in other countries.

hVIVO - World leading vaccine testing - high margins 30 - 40%
Global customer based - 12 leading Pharma vaccine companies
Transformational Covid-19 Antibody testing launched
ORPH £14.3M cash - £1.4M debt. Cash generative now.
VENN Life drug development
Existing combines near term target contracts for hVIVO and VENN £110M
Prospect pipeline in excess of £160M
Non core assets IMUTEX & PrEPBiopharm potential sale and dividend paid to shareholders
Not fogeting the assets too
LTHs GL enjoy the ride:
https://www.proactiveinvestors.co.uk/companies/news/920969/open-orphan-plc-proactive-one2one-virtual-event-920969.html

Too many panickers over a few pence, people who bought first thing probably panicked out, seen it all before with ncyt, gdr , odx to name a few... strategic long termers reap the benefits

Simple terms - more sells than buys, plus forced sellers or profit takers... Opportunity knocks.

Fear and greed strikes again, there’s not much I can say other than enjoy the ride. I’m lucky to be able to add at these prices gla holders. Now back to work.

I’d imagine CF is disappointed by the sp dip but it always happens, on the plus side it allows investors to acquire more at a very reasonable price. Thank you again, let’s see where it ends up today.

Touched a nerve have I, no the sp wouldn’t be at 12p or lower as you suggested it was already in the 15s when CF wanted calm the market down. The IIs are here for the long term as quoted by CF. I don’t need to back up my comments they’re all justified and backed by the assets CF has acquired at huge discounts to their true value. Read the company RNSs it’s all the evidence you need.

You get real, the business is grossly undervalued you clearly have an agenda to post negative spin about this company, with out any RNSs the sp would be naught in fact there would be a business. Stupid post move on.

The sp is consolidating nicely with more and more solid mews. Buy, add and hold for rewards.

Media exposure will be huge, well done CF, blue chip companies and pharma’s will be queuing to use our covid-19 antibody tests this is the start of something big...

They’re not going to raise again and they didn’t want to raise more as they don’t need it. It was a General discussion about the raise and CF said in hindsight they should have given more to the retail investors and if they did another raise they would. They got more than enough money now so stop trying to suggest otherwise. The revenues have started.

hVIVO COVID Clear Test "Transformational news" CF lots of news items due in the coming days.
Plus 5 x revenues streams to the business.
Very excited about the company prospects going forward.

Excellent - know wonder there was a big buyer earlier, 1M tests a year at £120 - £150 per = great revenue stream

There's your buyer 1M at 14.50p at 16.23